Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor

• DOI: 10.3389/fonc.2021.589022
• Publication Date: 2021-06-01T05:53:25Z
• Authors: Yang Chen; Cheng Zhang; Zhi Peng; Changsong Qi; Jifang Gong; Xiaotian Zhang; Jian Li; Lin Shen
• Keywords: Pulmonary and Respiratory Medicine; 0301 basic medicine; lymphocyte-to-monocyte ratio; Hazard ratio; Proportional hazards model; PD-1/PD-L1; Cancer Immunotherapy; 03 medical and health sciences; Inflammation's Role in Cancer Development and Progression; Health Sciences; Neutrophil-to-Lymphocyte Ratio; Confounding; prognostic biomarker; Internal medicine; RC254-282; Cancer; gastric cancer; Confidence interval; Gastroenterology; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Gastric Cancer Research and Treatment; Immune Checkpoint Blockade; 3. Good health; Oncology; Medicine; Biomarkers for Immunotherapy; immunotherapy

Optimal prognostic biomarkers for patients with gastric cancer who received immune checkpoint inhibitor (ICI) are lacking. Inflammatory markers including lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte (PLR), and systemic inflammation index (SII) easily available. However, its correlation ICI is unknown in cancer. Here, we evaluated the potential association between LMR, PLR, SII clinical outcomes undergoing therapy.We examined at baseline, 6 (± 2) weeks later 139 therapy August 2015 April 2019 Peking University Cancer Hospital (Beijing, China). Landmark analysis was conducted to explore value of on progress-free survival (PFS), overall (OS). A Cox proportional hazards model used compute mortality hazard ratios (HRs) adjusting confounders age, sex, ECOG, tumor location, differentiation, stage, line therapy, type anti-PD-1/PD-L1 therapy.Among patients, 103 (74.1%) were male, median age 60 years. Median duration cycles. We observed that both LMR baseline week independent factors. Patients a higher (≥ 3.5) or had superior PFS [baseline: HR 0.58, 95% confidence interval (CI): 0.38-0.91; 6: 0.48, CI: 0.29-0.78] OS (baseline: 0.38, 0.24-0.62; 0.52, 0.31-0.88) compared lower (< 3.5). Furthermore, ≥ 3.5 estimated have much better (HR 0.41, 0.23-0.72) 0.34, 0.18-0.64) than < 6.Baseline early changes strongly associated may serve identify most likely benefit from ICI.